🎉 M&A multiples are live!
Check it out!

Valneva Valuation Multiples

Discover revenue and EBITDA valuation multiples for Valneva and similar public comparables like AstraZeneca India, GSK India, and Prescient Therapeutics.

Valneva Overview

About Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.


Founded

1999

HQ

France
Employees

713

Website

valneva.com

Financials

LTM Revenue $189M

LTM EBITDA $13.2M

EV

$608M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Valneva Financials

Valneva has a last 12-month revenue of $189M and a last 12-month EBITDA of $13.2M.

In the most recent fiscal year, Valneva achieved revenue of $182M and an EBITDA of $34.5M.

Valneva expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Valneva valuation multiples based on analyst estimates

Valneva P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $165M $182M XXX XXX XXX
Gross Profit $39.6M $56.8M XXX XXX XXX
Gross Margin 24% 31% XXX XXX XXX
EBITDA -$62.0M $34.5M XXX XXX XXX
EBITDA Margin -38% 19% XXX XXX XXX
Net Profit -$154M -$109M XXX XXX XXX
Net Margin -93% -60% XXX XXX XXX
Net Debt n/a $54.5M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Valneva Stock Performance

As of April 15, 2025, Valneva's stock price is EUR 3 (or $3).

Valneva has current market cap of EUR 518M (or $557M), and EV of EUR 566M (or $608M).

See Valneva trading valuation data

Valneva Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$608M $557M XXX XXX XXX XXX $-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Valneva Valuation Multiples

As of April 15, 2025, Valneva has market cap of $557M and EV of $608M.

Valneva's trades at 3.2x LTM EV/Revenue multiple, and 46.0x LTM EBITDA.

Analysts estimate Valneva's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Valneva and 10K+ public comps

Valneva Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $608M XXX XXX XXX
EV/Revenue 3.3x XXX XXX XXX
EV/EBITDA 17.7x XXX XXX XXX
P/E -42.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Valneva Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Valneva Valuation Multiples

Valneva's NTM/LTM revenue growth is 18%

Valneva's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Valneva's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Valneva's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Valneva and other 10K+ public comps

Valneva Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 10% XXX XXX XXX XXX
EBITDA Margin 19% XXX XXX XXX XXX
EBITDA Growth -156% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 37% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 31% XXX XXX XXX XXX
G&A Expenses to Revenue 25% XXX XXX XXX XXX
R&D Expenses to Revenue 44% XXX XXX XXX XXX
Opex to Revenue 88% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Valneva Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Valneva M&A and Investment Activity

Valneva acquired  XXX companies to date.

Last acquisition by Valneva was  XXXXXXXX, XXXXX XXXXX XXXXXX . Valneva acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Valneva

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Valneva

When was Valneva founded? Valneva was founded in 1999.
Where is Valneva headquartered? Valneva is headquartered in France.
How many employees does Valneva have? As of today, Valneva has 713 employees.
Who is the CEO of Valneva? Valneva's CEO is Mr. Thomas Lingelbach.
Is Valneva publicy listed? Yes, Valneva is a public company listed on PAR.
What is the stock symbol of Valneva? Valneva trades under VLA ticker.
When did Valneva go public? Valneva went public in 2007.
Who are competitors of Valneva? Similar companies to Valneva include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Valneva? Valneva's current market cap is $557M
What is the current revenue of Valneva? Valneva's last 12-month revenue is $189M.
What is the current EBITDA of Valneva? Valneva's last 12-month EBITDA is $13.2M.
What is the current EV/Revenue multiple of Valneva? Current revenue multiple of Valneva is 3.2x.
What is the current EV/EBITDA multiple of Valneva? Current EBITDA multiple of Valneva is 46.0x.
What is the current revenue growth of Valneva? Valneva revenue growth between 2023 and 2024 was 10%.
Is Valneva profitable? Yes, Valneva is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.